Immunovant, Inc. · NASDAQ:IMVT
Immunovant — 2025 J.P. Morgan Healthcare Conference
21 slides from Immunovant's conference presentation, Jan 14, 2025
Slide 1: Targeted science, Tailored solutions
Targeted science, Tailored solutions for people with autoimmune disease 2025 J.P. Morgan Healthcare Conference January 14, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “ex
Slide 3: Our Company
Our Company
Slide 4: Our vision: Normal lives for people with autoimmune disease
Our vision: Normal lives for people with autoimmune disease What we do: We are developing targeted therapies that are designed to address the complex and variable needs of people with autoimmune diseases. Love Bolder, All Trailblazing Faster Voices 4
Slide 5: 2024: Many milestones achieved supporting lead asset IMVT-1402
2024: Many milestones achieved supporting lead asset IMVT-1402 Graves' POC observed greater benefit with deeper IgG reduction 5 INDs cleared for lead asset, IMVT-1402 Initiated IMVT-1402 pivotal trials in Graves' Disease & ACPA+ D2T RA1 Unprecedented speed of starting pivotal trials with autoinjecto
Slide 6: Our focus: Pursue a broad anti-FcRn strategy based on potential best-in-class profile of IMVT-1402
Our focus: Pursue a broad anti-FcRn strategy based on potential best-in-class profile of IMVT-1402 targeting autoantibody-driven diseases Leadership Intellectual Financial Validated Product Market Team Property Strength Target Candidates Opportunity Deep drug Strong patent Cash and cash FcRn is a va
Slide 7: Multiple near-term milestones for enhanced value creation
Multiple near-term milestones for enhanced value creation On track to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025 and trials in a total of 10 indications by March 31, 20261 IMVT-1402 Indications #1 and Indications #3 through All Indications through #10: #2: Trial
Slide 8: Graves' data demonstrates potentially transformational results in patients
Graves’ data demonstrates potentially transformational results in patients uncontrolled on ATDs with greater response driven by deeper IgG lowering Phase 2 batoclimab proof of concept data % of participants who achieve normal T3 and T4 or % of participants who achieve normal T3 and T4 or have T3 or
Slide 9: Graves' US market-sizing analyses confirm high unmet need
Graves’ US market-sizing analyses confirm high unmet need with ~330K prevalent patients relapsed, uncontrolled, or intolerant to ATDs Conservative Inovalon claims analysis1 yields ~880K prevalent Graves’ Disease patients, 1 including ~330K prevalent ATD relapsed patients choosing not to pursue ablat
Slide 10: Unmet medical need in Graves' disease was rated higher by thyroid specialists
Unmet medical need in Graves’ disease was rated higher by thyroid specialists after exposure to batoclimab data Percent of ATD-treated GD patients needing alternative medical therapy 53% 33% 60% increase after review of batoclimab data July 2024 December 2024 Source: Graves’ Disease HCP Quantitative
Slide 11: Unprecedented speed of starting pivotal trials with an autoinjector
Unprecedented speed of starting pivotal trials with an autoinjector 1 Years from first-in-human study for an asset to first-pivotal study2 with an autoinjector ~7.5 ~1.5 Immunovant IMVT-1402 Precedent MedianImmunology Products of Recently Approved Immunology Products & Comparable Programs in Develop
Slide 12: IMVT-1402 starting pivotal trials with intended commercial formulation and device: YpsoMate autoinjector
IMVT-1402 starting pivotal trials with intended commercial formulation and device: YpsoMate® autoinjector Leveraging market-proven, user-friendly technology to meet patient needs IMVT-1402 2.25 mL automated disposable Established autoinjector with multiple injection device approved products • Automa
Slide 13: Our Market
Our Market... +++ + + + + +++ +
Slide 14: 2024: Many positive developments for the FcRn inhibitor class
2024: Many positive developments for the FcRn inhibitor class Positive data Approval in Mixed results Growing KOL in new new from enthusiasm for indications1 indication2 other modalities3 earlier line anti- FcRn use Ever-growing conviction in anti-FcRn as a uniquely exciting class 1. https://us.arge
Slide 15: Our Differentiation
Cc 2 — ase —_ c& ra cab) te a) 5 O + + + c ay + + + + + + + + Yf IMMUNOVANT
Slide 16: Our differentiated value proposition: Three potentially unique attributes to address unmet patient needs
Our differentiated value proposition: Three potentially unique attributes to address unmet patient needs Subcutaneous injection To enable self-administration at home Tailored dosing Rapid & deep IgG reduction To help alleviate Strong correlation between deep symptoms across disease IgG reduction and
Slide 17: Our lead asset: IMVT-1402 has a combination of potentially best-in-class attributes
Our lead asset: IMVT-1402 has a combination of potentially best-in-class attributes not seen with other anti-FcRns IMVT-1402 Deep IgG Lowering Phase 1 data suggests deep dose- + + dependent IgG lowering + Favorable Analyte Profile Phase 1 data supports a favorable analyte profile with no or minimal
Slide 18: An exciting 2025
Ke) N O N op c = O ~< o c <
Slide 19: 2025: Exciting year ahead
2025: Exciting year ahead MG and CIDP data (CYQ1) and TED data (CYH2) designed to reinforce 01 correlation of greater efficacy with deeper IgG reduction Additional data from Graves’ POC including 6-month remission data 02 designed to further articulate potential for IMVT-1402 in Graves’ Potentially
Slide 20: Multiple near-term milestones for enhanced value creation
Multiple near-term milestones for enhanced value creation On track to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025 and trials in a total of 10 indications by March 31, 20261 IMVT-1402 Indications #1 and Indications #3 through All Indications through #10: #2: Trial
Slide 21: Thank you
Thank you + + +++ + + + +